Abdo, Mustafa http://orcid.org/0000-0002-3300-1398
Watz, Henrik
Veith, Vera
Kirsten, Anne-Marie
Biller, Heike
Pedersen, Frauke
von Mutius, Erika
Kopp, Matthias V.
Hansen, Gesine
Waschki, Benjamin
Rabe, Klaus F.
Trinkmann, Frederik
Bahmer, Thomas
Article History
Received: 29 June 2020
Accepted: 11 October 2020
First Online: 21 October 2020
Ethics approval and consent to participate
: The study is a part from the prospective longitudinal All Age Asthma Cohort (ALLIANCE). The study was approved by local ethics committee at Medical School Luebeck, Germany, and is registered at clinicaltrials.gov (pediatric arm: NCT02496468; adult arm: NCT02419274).
: Not applicable.
: MA reports no conflict of interest. HW reports personal fees and study honoraria of his employer from AstraZeneca, Boehringer Ingelheim, BerlinChemie, Chiesi, Novartis, GSK, and Sanofi outside the submitted work. VV reports no conflict of interest. AMK reports personal fees and study honoraria of her employer from AstraZeneca, Boehringer Ingelheim, BerlinChemie, Chiesi, Novartis, GSK, and Sanofi outside the submitted work. HB reports no conflict of interest. FP reports no conflict of interest. During the 36 months prior to publication, EvM Mutius reports to have received personal fees from Pharmaventures, from OM Pharma S. A., from Springer-Verlag GmbH, from Elsevier GmbH and Elsevier Ltd., from Peptinnovate Ltd., from Turun Yliopisto, from Tampereen Yliopisto, from Helsingin Yliopisto, from European Respiratory Society, from Deutsche Pharmazeutische Gesellschaft e. V., from Massachusetts Medical Society, from Chinese University of Hongkong, from European Commission, from Böhringer Ingelheim International GmbH, from Universiteit Utrecht, Faculteit Diergeneeskunde, from Universität Salzburg, from Georg Thieme Verlag, from Japanese Society of Pediatric Allergy and Clinical Immunology (JSPACI), outside the submitted work; In addition, Dr. von Mutius has a patent LU101064—Barn dust extract for the prevention and treatment of diseases pending, a patent EP2361632: Specific environmental bacteria for the protection from and/or the treatment of allergic, chronic inflammatory and/or autoimmune disorders with royalties paid to ProtectImmun GmbH, a patent Publication number EP 1411977: Composition containing bacterial antigens used for the prophylaxis and the treatment of allergic diseases, licensed to ProtectImmun GmbH, a patent Publication number EP1637147: Stable dust extract for allergy protection licensed to ProtectImmun GmbH, and a patent Publication number EP 1964570: Pharmaceutical compound to protect against allergies and inflammatory diseases licensed to ProtectImmun GmbH. MVK reports no conflict of interest. GH reports no conflict of interest. BW reports no conflict of interest. KFR reports personal fees from AstraZeneca, Boehringer Ingelheim, BerlinChemie, Chiesi, Novartis, GSK, and Sanofi outside the submitted work. FT received travel support from Actelion, Berlin Chemie, Boehringer Ingelheim, Chiesi, Novartis, Mundipharma and TEVA as well as speaker or consultation fees from AstraZeneca, Berlin Chemie, Boehringer Ingelheim, Bristol-Myers Squibb, Chiesi, GlaxoSmithKline, Novartis and Roche, Sanofi aventis, all outside the submitted work. TB reports personal fees from AstraZeneca, Boehringer Ingelheim, BerlinChemie, Chiesi, Novartis, GSK, and Sanofi outside the submitted work.